Skip to Main Content

Biosimilars, a much-lauded approach to reducing drug costs in the United States, are still underused here, even as they are proving successful in Europe. Why? Two key reasons are misperceptions of inferiority and the intricacies of U.S. market access.

As the head of U.S. market access for Samsung Bioepis, a South Korean developer and manufacturer of biosimilars, I routinely introduce our capabilities to key stakeholders in the U.S. health care market. Early after their introduction, the U.S. market showed little desire to embrace or use biosimilars. This sentiment largely held regardless of whether it was the public or private sector, an academic medical center or independent practice, and regardless of therapeutic area.

advertisement

Since then, as the market has become better informed, there has been an increased willingness to prescribe biosimilars. Yet market uptake overall is still slow, and clearly there is a need for policies that will accelerate biosimilar use to lower systemwide costs.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.